# Tomasz M. Beer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tomasz-m-beer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,610 |
| Field | Prostate Cancer Treatment and Research |
| h-index | 82 |
| i10-index | 282 |
| Last Known Institution | Oregon Health & Science University |
| OpenAlex ID | https://openalex.org/A5048477205 |
| ORCID iD | https://orcid.org/0000-0001-5600-9993 |
| Works | 801 |

## Researcher papers

- [Enzalutamide in Metastatic Prostate Cancer before Chemotherapy](https://scholariq.org/papers/enzalutamide-in-metastatic-prostate-cancer-before-chemotherapy/)
- [Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer](https://scholariq.org/papers/lutetium-177-psma-617-for-metastatic-castration-resistant-prostate-cancer/)
- [Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group](https://scholariq.org/papers/design-and-end-points-of-clinical-trials-for-patients-with-progressive-prostate/)
- [Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3](https://scholariq.org/papers/trial-design-and-objectives-for-castration-resistant-prostate-cancer-updated/)
- [Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer](https://scholariq.org/papers/genomic-hallmarks-and-structural-variation-in-metastatic-prostate-cancer/)
- [Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-the-report-of-the-advanced/)
- [Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-report-of-the-advanced/)
- [Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors](https://scholariq.org/papers/analysis-of-circulating-cell-free-dna-identifies-multiclonal-heterogeneity-of-i/)
- [Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022](https://scholariq.org/papers/management-of-patients-with-advanced-prostate-cancer-metastatic-and-or/)

## Researcher topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Radiopharmaceutical Chemistry and Applications](https://scholariq.org/topics/radiopharmaceutical-chemistry-and-applications/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Oregon Health & Science University](https://scholariq.org/institutions/oregon-health-and-science-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.